Table 1.
Compound | Half maximum inhibitory concentration in µM (IC50) a | ΔTm (°C) b | |||
---|---|---|---|---|---|
DU-145 c | A-549 d | HeLa e | HEK-293 f | ||
doxorubicin | 1.28 ± 0.2 | 0.85 ± 0.1 | 0.91 ± 0.2 | NT | 9.5 |
[3](CF3SO3)4 | 0.54 ± 0.2 | 0.50 ± 0.1 | 0.52 ± 0.2 | 62.0 ± 0.5 | 12.9 |
[4](CF3SO3)4 | 16.0 ± 0.4 | 3.18 ± 0.2 | 4.16 ± 0.3 | 31.2 ± 0.5 | 6.8 |
[5](CF3SO3)4 | 4.67 ± 0.2 | 0.67 ± 0.1 | 1.01 ± 0.3 | 41.3 ± 0.4 | 7.3 |
[6](CF3SO3)4 | 2.53 ± 0.2 | 0.84 ± 0.1 | 1.04 ± 0.3 | 40.3 ± 0.4 | 7.9 |
[7](CF3SO3)4 | 4.98 ± 0.3 | 2.01 ± 0.2 | 5.75 ± 0.2 | 62.1 ± 0.3 | 8.2 |
[8](CF3SO3)4 | 0.72 ± 0.2 | 0.67 ± 0.4 | 0.59 ± 0.2 | 70.8 ± 0.4 | 12.7 |
a 50% Inhibitory concentration, values averaged over three individual experiments; b Melting temperature measurements were performed after incubation for 12 h at 37 °C in PE buffer (10 mM NaH2PO4/Na2HPO4, 1 mM Na2EDTA) at pH 7.4 with a complex/DNA ratio of 1:1. CT DNA alone melts at 59.3 °C; c Prostate cancer; d Lung cancer; e Cervical cancer; f Normal human embryonic kidney cells; NT: Not tested.